These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 33830427)

  • 21. Olanzapine augmentation of serotonin uptake inhibitors in obsessive-compulsive disorder: an open study.
    Francobandiera G
    Can J Psychiatry; 2001 May; 46(4):356-8. PubMed ID: 11387793
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of aripiprazole augmentation of serotonin reuptake inhibitors or clomipramine in treatment-resistant obsessive-compulsive disorder: a double-blind, placebo-controlled study.
    Muscatello MR; Bruno A; Pandolfo G; Micò U; Scimeca G; Romeo VM; Santoro V; Settineri S; Spina E; Zoccali RA
    J Clin Psychopharmacol; 2011 Apr; 31(2):174-9. PubMed ID: 21346614
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A systematic review of the use of risperidone, paliperidone and aripiprazole as augmenting agents for obsessive-compulsive disorder.
    Brakoulias V; Stockings E
    Expert Opin Pharmacother; 2019 Jan; 20(1):47-53. PubMed ID: 30360669
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Olanzapine augmentation of fluvoxamine-refractory obsessive-compulsive disorder (OCD): a 12-week open trial.
    Bogetto F; Bellino S; Vaschetto P; Ziero S
    Psychiatry Res; 2000 Oct; 96(2):91-8. PubMed ID: 11063782
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A Promising Preliminary Study of Aripiprazole for Treatment-Resistant Childhood Obsessive-Compulsive Disorder.
    Ercan ES; Ardic UA; Ercan E; Yuce D; Durak S
    J Child Adolesc Psychopharmacol; 2015 Sep; 25(7):580-4. PubMed ID: 26375768
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Ondansetron augmentation in patients with obsessive-compulsive disorder who are inadequate responders to serotonin reuptake inhibitors: improvement with treatment and worsening following discontinuation.
    Pallanti S; Bernardi S; Antonini S; Singh N; Hollander E
    Eur Neuropsychopharmacol; 2014 Mar; 24(3):375-80. PubMed ID: 24406025
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Clinical features of patients with obsessive-compulsive disorder showing different pharmacological responses].
    Sumitani S; Ueno S; Ishimoto Y; Taniguchi T; Tomotake M; Motoki I; Yamauchi K; Ohmori T
    Seishin Shinkeigaku Zasshi; 2006; 108(12):1282-92. PubMed ID: 17334085
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacological augmentation of serotonin reuptake inhibitors in patients with obsessive-compulsive disorder: A network meta-analysis.
    Maiti R; Mishra A; Srinivasan A; Mishra BR
    Acta Psychiatr Scand; 2023 Jul; 148(1):19-31. PubMed ID: 37177823
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of aripiprazole augmentation in treatment-resistant obsessive-compulsive disorder (a double blind clinical trial).
    Sayyah M; Sayyah M; Boostani H; Ghaffari SM; Hoseini A
    Depress Anxiety; 2012 Oct; 29(10):850-4. PubMed ID: 22933237
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Atypical antipsychotic augmentation in SSRI treatment refractory obsessive-compulsive disorder: a systematic review and meta-analysis.
    Veale D; Miles S; Smallcombe N; Ghezai H; Goldacre B; Hodsoll J
    BMC Psychiatry; 2014 Nov; 14():317. PubMed ID: 25432131
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Augmentation strategy with olanzapine in resistant obsessive compulsive disorder: an Italian long-term open-label study.
    Marazziti D; Pfanner C; Dell'Osso B; Ciapparelli A; Presta S; Corretti G; Di Nasso E; Mungai F; Dell'Osso L
    J Psychopharmacol; 2005 Jul; 19(4):392-4. PubMed ID: 15982994
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Ondansetron augmentation in treatment-resistant obsessive-compulsive disorder: a preliminary, single-blind, prospective study.
    Pallanti S; Bernardi S; Antonini S; Singh N; Hollander E
    CNS Drugs; 2009 Dec; 23(12):1047-55. PubMed ID: 19958042
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Brazilian Research Consortium on Obsessive-Compulsive Spectrum Disorders guidelines for the treatment of adult obsessive-compulsive disorder. Part I: pharmacological treatment.
    de Oliveira MVS; de Barros PMF; de Mathis MA; Boavista R; Chacon P; Echevarria MAN; Ferrão YA; Vattimo EFQ; Lopes AC; Torres AR; Diniz JB; Fontenelle LF; Rosário MCD; Shavitt RG; Miguel EC; da Silva RMF; Costa DLDC
    Braz J Psychiatry; 2023 May; 45(2):146-161. PubMed ID: 36749887
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Double-blind, placebo-controlled, pilot trial of paliperidone augmentation in serotonin reuptake inhibitor-resistant obsessive-compulsive disorder.
    Storch EA; Goddard AW; Grant JE; De Nadai AS; Goodman WK; Mutch PJ; Medlock C; Odlaug B; McDougle CJ; Murphy TK
    J Clin Psychiatry; 2013 Jun; 74(6):e527-32. PubMed ID: 23842022
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Quetiapine augmentation of serotonin reuptake inhibitors in obsessive-compulsive disorder.
    Mohr N; Vythilingum B; Emsley RA; Stein DJ
    Int Clin Psychopharmacol; 2002 Jan; 17(1):37-40. PubMed ID: 11800505
    [TBL] [Abstract][Full Text] [Related]  

  • 36. 8-week, single-blind, randomized trial comparing risperidone versus olanzapine augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder.
    Maina G; Pessina E; Albert U; Bogetto F
    Eur Neuropsychopharmacol; 2008 May; 18(5):364-72. PubMed ID: 18280710
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Topiramate augmentation in treatment-resistant obsessive-compulsive disorder: a retrospective, open-label case series.
    Van Ameringen M; Mancini C; Patterson B; Bennett M
    Depress Anxiety; 2006; 23(1):1-5. PubMed ID: 16178009
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Aripiprazole versus quetiapine in treatment-resistant obsessive-compulsive disorder: a double-blind clinical trial.
    Shoja Shafti S; Kaviani H
    Ther Adv Psychopharmacol; 2015 Feb; 5(1):32-7. PubMed ID: 25653829
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Olanzapine augmentation for treatment-resistant obsessive-compulsive disorder.
    Koran LM; Ringold AL; Elliott MA
    J Clin Psychiatry; 2000 Jul; 61(7):514-7. PubMed ID: 10937610
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Augmentation agents to serotonin reuptake inhibitors for treatment-resistant obsessive-compulsive disorder: A network meta-analysis.
    Zhou DD; Zhou XX; Li Y; Zhang KF; Lv Z; Chen XR; Wan LY; Wang W; Wang GM; Li DQ; Ai M; Kuang L
    Prog Neuropsychopharmacol Biol Psychiatry; 2019 Mar; 90():277-287. PubMed ID: 30576763
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.